Hos patienter, som er i plateaufase (mere end 50% reduktion af myelom- protein) efter initial induktionskemoterapi, kan interferon alfa- 2b gives som monoterapi, subkutant i en dosering på 3 millioner IE/ m2 tre gange om ugen (hver anden dag).
In patients who are in the plateau phase (more than 50% reduction of myeloma protein) following initial induction chemotherapy, interferon alfa-2b may be administered as monotherapy, subcutaneously, at a dose of 3 million IU/ m2 three times a week (every other day).